Reference

1. Mc Bride WG. 1961. Thalidomide and congenital abnormalities. Lancet. 278,358. http://dx.doi.org/10.1016/S0140-6736(61)90927-8
2. Bégaud B, Chaslerie A, Haramburu F. 1994. Organization and results of drug vigilance in France. Rev Epidemiol Sante Publique. PubMed 42, 416-23.
3. WHO. The Importance of Pharmacovigilance, Safety Monitoring of medicinal products. World Health Organization 2002.
4. Report E. Effective communications in Pharmacovigilance. International Conference on Developing Effective Communications in Pharmacovigilance, Erice, Sicily 1997; 24-27.
5. Shuka SS, Gidwani B, Pandey R, Rao SP, Singh V, et al. 2012. Importance of Pharmacovigilance in Indian Pharmaceutical Industry. Asian J. Res. Pharm. Sci. 2, 4-8.
6. 6. Hornbuckle K, Wu H-H, Fung MC. 1999. Evaluation of spontaneous adverse event reports by primary reporter - a 15-year review (1983 to 1997). Drug Inf J. 33, 1117-24.
7. WHO. 2000. Consumer reporting of ADRs. WHO Drug Information. 14, 211-15.
8. Egberts GPG, Smulderes M, De Konig FHP, et al. 1996. Can adverse drug reactions be detected earlier?: a comparison of reports by patients and professionals. BMJ. 313, 530-31. PubMed http://dx.doi.org/10.1136/bmj.313.7056.530
9. Norwood PK, Sampson AR. 1988. A statistical methodology for postmarketing surveillance of adverse drug reaction reports. Stat Med. 7, 1023-30. PubMed http://dx.doi.org/10.1002/sim.4780071004
10. Whitebread S, Hamon J, Bojanic D, Urban L. 2005. Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development. Drug Discov Today. 10, 1421-33. PubMed http://dx.doi.org/10.1016/S1359-6446(05)03632-9
11. McClure DL. 2009. Improving Drug Safety: Active Surveillance Systems Should be Paramount.
12. Pharmaceutical Medicine. 23, 127-30. http://dx.doi.org/10.1007/BF03256760.
13. Shibata A, Hauben M. Pharmacovigilance, signal detection and signal intelligence overview. Proceedings of the 14th International Conference on Information Fusion (FUSION-2011). Chicago, IL. 2011; pp. 1-7.
14. Lopes P, Nunes T, Campos D, Furlong LI, Bauer-Mehren A, et al. 2013. Gathering and Exploring Scientific Knowledge in Pharmacovigilance. PLoS ONE. 8(12), e83016. PubMed http://dx.doi.org/10.1371/journal.pone.0083016.
15. Stahl M, Edwards IR, Bowring G, Kiuru A, Lindquist M. 2003. Assessing the Impact of Drug Safety Signals from the WHO Database Presented inSIGNAL': Results from a Questionnaire of National Pharmacovigilance Centres. Drug Saf. PubMed 26, 721-27.
16. Lazarou J, Pomeranz BH, Corey PN. 1998. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 279, 1200-05. PubMed http://dx.doi.org/10.1001/jama.279.15.1200
17. Meyboom RHB, Lindquist M, Egberts ACG, Edwards IR. 2002. Signal Selection and Follow- Up in Pharmacovigilance. Drug Saf. 25, 459-65. PubMed http://dx.doi.org/10.2165/00002018200225060-00011.
18. De Bruin ML, Van Puijenbroek EP, Egberts AC, Hoes AW, Leufkens HG. 2002. Nonsedating antihistamine drugs and cardiac arrhythmias– biased risk estimates from spontaneous reporting systems? Br J Clin Pharmacol. 53, 370-74. PubMed http://dx.doi.org/10.1046/j.13652125.2002.01569.x
19. Coloma PM, Schuemie MJ, Trifirò G, Gini R, Herings R, et al. 2011. Combining electronic healthcare databases in Europe to allow for largescale drug safety monitoring: the EU-ADR Project. Pharmacoepidemiol Drug Saf. 20, 1-11. PubMed http://dx.doi.org/10.1002/pds.2053.
20. Härmark L, van Grootheest AC. 2008. Pharmacovigilance: methods, recent developments and future perspectives. Eur J Clin Pharmacol. 64, 743-52. PubMed http://dx.doi.org/10.1007/s00228-008-0475-9.
21. Basic steps in Pharmacovigilance Case Processing [cited on 30/7/2015]; Available at URL:http://www.pharmawisdom.com/Basic-steps-in-Pharmacovigilance-Case rocessing.html